Imaxe de Portada

Modern Pharmaceutics for Cardiovascular Diseases

Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite...

Descrición completa

Gardado en:
Formato: Online
Idioma:inglés
Publicado: MDPI - Multidisciplinary Digital Publishing Institute 2024
Subjects:
aspirin
coronary artery disease prevention
gastric protection
micronization
collagen cogrinding
arterial hypertension
HTN
nuclear factor erythroid factor 2-related factor 2
Nrf2
oxidative stress
antioxidant
atherosclerosis
pharmacotherapy
emergent therapeutics
natural anti-atherosclerotic products
lipids
lipoproteins
small dense LDL
cholesterol
prevention
therapy
inflammation
colchicine
NLRP3 inflammasome
coronary artery disease
acute coronary syndrome
heart failure
contractility
calcium
cardiomyocyte
myofilament
HDAC inhibitor
antifibrotic strategies
cardiac fibrosis
cardiovascular diseases
fibrosis pathways
therapeutic strategies
regenerative medicine
cell-free secretomes
paracrine factors
single-cell RNA sequencing
serine protease inhibitor
endothelial barrier
renin-angiotensin-aldosterone system
RAAS
angiotensin-converting enzyme-2
ACE2
angiotensin 1-7
Ang (1-7)
COVID-19
long-term effects
angiotensin receptor–neprilysin inhibitor
sodium-glucose co-transporter-2 inhibitors
soluble guanylate cyclase activator
cardiac myosin activation
autonomic modulation
SGLT2i
empagliflozin
NHE1
NHE11
sodium channel
thema EDItEUR::M Medicine and Nursing
Acceso en liña:ONIX_20240514_9783036599809_49
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Internet

ONIX_20240514_9783036599809_49

Títulos similares